Selenium inhibits growth of trastuzumab-resistant human breast cancer cells via downregulation of Akt and beclin-1.

The response rate to treatment with trastuzumab (Tz), a recombinant humanized anti-HER2 monoclonal antibody, is only 12-34% despite demonstrated effectiveness on improving the survival of patients with HER2-positive breast cancers. Selenium has an antitumor effect against cancer cells and can play a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Joohyun Woo, Jong Bin Kim, Taeeun Cho, Eun Hye Yoo, Byung-In Moon, Hyungju Kwon, Woosung Lim
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/78b47d50ead644189f86b73bdae4f555
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!